Table 4.
Dasatinib (N = 87) | Nilotinib (N = 87) | |
---|---|---|
Treatment discontinuation, N(%) | 18 (21) | 20 (23) |
Reason for discontinuation, N (% among discontinued patients) | ||
Toxicity | 4 (22) | 6 (30) |
Toxicity and resistance | 2 (11) | 0 (0) |
Resistance/Progression | 6 (33) | 5 (25) |
Death | 0 (0) | 1 (5) |
Financial | 1 (6) | 4 (20) |
Patient choice | 3 (17) | 1 (5) |
Non-adherence | 2 (11) | 3 (15) |